{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:21:07Z","timestamp":1793852467005,"version":"4.6.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmoop.2025.106054","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:36:51Z","timestamp":1773261411000},"page":"106054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8619-412X","authenticated-orcid":false,"given":"F.","family":"Gay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5240-5611","authenticated-orcid":false,"given":"G.","family":"Buda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1018-5139","authenticated-orcid":false,"given":"N.","family":"Bolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0997-4157","authenticated-orcid":false,"given":"D.","family":"Derudas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mangiacavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Montefusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Antonioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Baril\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4263-9032","authenticated-orcid":false,"given":"M.","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bertazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3785-9824","authenticated-orcid":false,"given":"G.","family":"Bertuglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9956-8164","authenticated-orcid":false,"given":"R.","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Carlisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4291-8875","authenticated-orcid":false,"given":"M.L.D.","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5641-231X","authenticated-orcid":false,"given":"R.","family":"Della Pepa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0769-6891","authenticated-orcid":false,"given":"A.","family":"Gozzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0948-9343","authenticated-orcid":false,"given":"C.","family":"Liberatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8504-3231","authenticated-orcid":false,"given":"E.A.","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4630-753X","authenticated-orcid":false,"given":"F.","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4398-7860","authenticated-orcid":false,"given":"S.","family":"Mor\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8248-2343","authenticated-orcid":false,"given":"L.","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pezzatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ribolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4219-6182","authenticated-orcid":false,"given":"R.","family":"Roncato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2348-5437","authenticated-orcid":false,"given":"B.","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5447-1068","authenticated-orcid":false,"given":"N.","family":"Sgherza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Vassallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.I.","family":"Vincelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3600-9310","authenticated-orcid":false,"given":"T.","family":"Za","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Musto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-7305","authenticated-orcid":false,"given":"E.","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.esmoop.2025.106054_bib1","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1091\/mbc.e12-01-0045","article-title":"NESdb: a database of NES-containing CRM1 cargoes","volume":"23","author":"Xu","year":"2012","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.esmoop.2025.106054_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-014-0085-1","article-title":"Nucleo-cytoplasmic transport as a therapeutic target of cancer","volume":"7","author":"Gravina","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106054_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2018.03.003","article-title":"Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma","volume":"18","author":"Gandhi","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"10.1016\/j.esmoop.2025.106054_bib4","doi-asserted-by":"crossref","first-page":"9487","DOI":"10.1016\/j.bmc.2008.09.051","article-title":"Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action","volume":"16","author":"Van Neck","year":"2008","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106054_bib5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein XPO1 \u2013 from biology to targeted therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"26","key":"10.1016\/j.esmoop.2025.106054_bib6","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1200\/JCO.2016.67.6346","article-title":"Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma","volume":"34","author":"Gounder","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.106054_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1030991","article-title":"Selinexor, a selective inhibitor of nuclear export, inhibits human neutrophil extracellular trap formation in vitro","volume":"13","author":"Baron","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.esmoop.2025.106054_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.semcancer.2014.03.002","article-title":"Atomic basis of CRM1-cargo recognition, release and inhibition","volume":"27","author":"Fung","year":"2014","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106054_bib9","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.18632\/oncotarget.6495","article-title":"A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds","volume":"7","author":"Crochiere","year":"2016","journal-title":"Oncotarget"},{"issue":"39","key":"10.1016\/j.esmoop.2025.106054_bib12","doi-asserted-by":"crossref","first-page":"25529","DOI":"10.18632\/oncotarget.25368","article-title":"Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death","volume":"9","author":"Argueta","year":"2018","journal-title":"Oncotarget"},{"issue":"48","key":"10.1016\/j.esmoop.2025.106054_bib13","doi-asserted-by":"crossref","first-page":"78883","DOI":"10.18632\/oncotarget.12428","article-title":"Selinexor, a selective inhibitor of nuclear export (SINE) compound, acts through NF-\u03baB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"issue":"48","key":"10.1016\/j.esmoop.2025.106054_bib14","doi-asserted-by":"crossref","first-page":"78896","DOI":"10.18632\/oncotarget.12969","article-title":"XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I\u03baB\u03b1 and overcomes acquired proteasome inhibitor resistance in human multiple myeloma","volume":"7","author":"Turner","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106054_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106054_bib16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-016-0304-z","article-title":"Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors","volume":"9","author":"Turner","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2025.106054_bib17","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1158\/0008-5472.CAN-19-0677","article-title":"Melphalan and exportin 1 inhibitors exert synergistic antitumor effects in preclinical models of human multiple myeloma","volume":"80","author":"Turner","year":"2020","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.esmoop.2025.106054_bib18","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1182\/blood.V128.22.3298.3298","article-title":"Synergistic anti-tumor effect of KPT-8602, a second generation Selective Inhibitor of Nuclear Export (SINE) compound, and panobinostat, a Pan-Histone Deacetylase (HDAC) inhibitor in multiple myeloma","volume":"128","author":"Argueta","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106054_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1158\/1535-7163.MCT-15-0488","article-title":"Synergistic myeloma cell death via novel intracellular activation of caspase-10-dependent apoptosis by carfilzomib and selinexor","volume":"15","author":"Rosebeck","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.106054_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-140485","article-title":"Characterization of synergistic selinexor combinations of dexamethasone, pomalidomide, elotuzumab and daratumumab in primary MM samples ex vivo","volume":"136","author":"Shain","year":"2020","journal-title":"Blood"},{"issue":"19_Supplement","key":"10.1016\/j.esmoop.2025.106054_bib21","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2014-1772","article-title":"Abstract 1772: Overcoming drug-resistance in multiple myeloma by CRM1 inhibitor combination therapy","volume":"74","author":"Turner","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2025.106054_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1275329","article-title":"Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors","volume":"14","author":"Binder","year":"2023","journal-title":"Front Immunol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.106054_bib23","doi-asserted-by":"crossref","first-page":"6930","DOI":"10.1182\/blood-2023-190413","article-title":"Sequential administration of selinexor and CAR-T therapy in relapsed\/refractory multiple myeloma","volume":"142","author":"Gill","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.esmoop.2025.106054_bib24","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.106054_bib25","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1182\/blood-2019-129038","article-title":"Response to therapy and the effectiveness of treatment with selinexor and dexamethasone in patients with penta-exposed triple-class refractory myeloma who had plasmacytomas","volume":"134","author":"Yee","year":"2019","journal-title":"Blood"},{"issue":"10262","key":"10.1016\/j.esmoop.2025.106054_bib26","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"issue":"Supplement 1","key":"10.1016\/j.esmoop.2025.106054_bib27","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-146003","article-title":"Clinical outcomes in patients (Pts) with dose reduction of selinexor in combination with bortezomib, and dexamethasone (XVd) in previously treated multiple myeloma from the boston study","volume":"138","author":"Jagannath","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106054_bib28","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/ejh.14223","article-title":"Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed\/refractory multiple myeloma: extended follow-up subgroup analysis of the BOSTON trial","volume":"113","author":"Mateos","year":"2024","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.106054_bib29","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.clml.2023.07.013","article-title":"Real world efficacy and toxicity of selinexor: importance of patient characteristics, dose intensity and post progression outcomes","volume":"23","author":"Kastritis","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.esmoop.2025.106054_bib30","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/s41375-020-0756-6","article-title":"Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials","volume":"34","author":"Gavriatopoulou","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106054_bib31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.clml.2019.12.026","article-title":"Consensus recommendations for the clinical management of patients with multiple myeloma treated with selinexor","volume":"20","author":"Mikhael","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.esmoop.2025.106054_bib32","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/j.clml.2022.01.014","article-title":"Guidance for use and dosing of selinexor in multiple myeloma in 2021: consensus From International Myeloma Foundation Expert Roundtable","volume":"22","author":"Nooka","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.esmoop.2025.106054_bib35","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1007\/s00277-022-04999-1","article-title":"Efficacy and safety of selinexor-based regimens for relapsed\/refractory multiple myeloma: a systematic review of literature","volume":"101","author":"Masood","year":"2022","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.106054_bib36","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106054_bib37","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clml.2018.01.006","article-title":"Assessing the effect of adherence on patient-reported outcomes and out of pocket costs among patients with multiple myeloma","volume":"18","author":"Gupta","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.106054_bib38","doi-asserted-by":"crossref","first-page":"10065","DOI":"10.1182\/blood-2022-160228","article-title":"Association of socioeconomic status with adherence, progression free and overall survival to oral agents in multiple myeloma patients","volume":"140","author":"Rutter","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106054_bib39","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/1078155220980807","article-title":"Adherence to and effectiveness of lenalidomide after 1 year of treatment in a real world setting","volume":"28","author":"Santoleri","year":"2022","journal-title":"J Oncol Pharm Pract"},{"issue":"10","key":"10.1016\/j.esmoop.2025.106054_bib40","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.clml.2022.05.003","article-title":"Real world adherence to and persistence with oral oncolytics in multiple myeloma: a systematic review and meta-analysis","volume":"22","author":"Naser","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106054_bib41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10238-025-01683-2","article-title":"Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home","volume":"25","author":"Bigi","year":"2025","journal-title":"Clin Exp Med"},{"issue":"9","key":"10.1016\/j.esmoop.2025.106054_bib42","doi-asserted-by":"crossref","first-page":"e1475","DOI":"10.1200\/OP.22.00008","article-title":"Medication adherence among adults with comorbid chronic conditions initiating oral anticancer agent therapy for multiple myeloma","volume":"18","author":"Gatwood","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"10.1016\/j.esmoop.2025.106054_bib43","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s00277-021-04543-7","article-title":"Oral therapy adherence and satisfaction in patients with multiple myeloma","volume":"100","author":"Solano","year":"2021","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106054_bib44","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/geront\/29.6.798","article-title":"Application of a multidimensional caregiver burden inventory","volume":"29","author":"Novak","year":"1989","journal-title":"Gerontologist"},{"key":"10.1016\/j.esmoop.2025.106054_bib45","series-title":"An investigation of the dimensions of burden in family caregivers of Alzheimer\u2019s disease patients. Unpublished master\u2019s degree thesis","author":"Guest","year":"1986"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106054_bib46","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/geront\/20.6.649","article-title":"Relatives of the impaired elderly: correlates of feelings of burden","volume":"20","author":"Zarit","year":"1980","journal-title":"Gerontologist"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106054_bib47","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/0164027585007003002","article-title":"Caregiving strain and the desire to institutionalize family members with Alzheimer\u2019s disease. Possible predictors and model development","volume":"7","author":"Morycz","year":"1985","journal-title":"Res Aging"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106054_bib48","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/geronj\/39.2.230","article-title":"Families caring for elders in residence: issues in the measurement of burden","volume":"39","author":"Poulshock","year":"1984","journal-title":"J Gerontol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106054_bib49","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106054_bib50","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2019.219139","article-title":"Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs","volume":"105","author":"Montefusco","year":"2020","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.esmoop.2025.106054_bib51","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3390\/cancers17071168","article-title":"Forcing ahead: second-line treatment options for lenalidomide-refractory multiple myeloma","volume":"17","author":"Mancuso","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.esmoop.2025.106054_bib52","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1016\/j.clml.2023.06.001","article-title":"Selinexor-based triplet regimens in patients with multiple myeloma previously treated with anti-CD38 monoclonal antibodies","volume":"23","author":"Schiller","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106054_bib53","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1158\/0008-5472.CAN-24-0886","article-title":"The functional transcriptomic landscape informs therapeutic strategies in multiple myeloma","volume":"85","author":"Sudalagunta","year":"2025","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.esmoop.2025.106054_bib54","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA\u2013EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.106054_bib55","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/ajh.26261","article-title":"Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by cytogenetic risk","volume":"96","author":"Richard","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106054_bib56","first-page":"384","article-title":"Efficacy of selinexor in relapsed\/refractory multiple myeloma (RRMM) patients with del17p and other high-risk abnormalities (a retrospective single-center study)","volume":"14","author":"Ehsan","year":"2024","journal-title":"Life (Basel)"},{"issue":"24","key":"10.1016\/j.esmoop.2025.106054_bib57","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106054_bib58","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/ndt\/gfz211","article-title":"Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry","volume":"36","author":"Courant","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106054_bib59","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1002\/ajh.26434","article-title":"Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: subgroup analysis from the BOSTON study","volume":"97","author":"Delimpasi","year":"2022","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.106054_bib60","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bjh.15969","article-title":"Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed\/refractory multiple myeloma","volume":"186","author":"Jakubowiak","year":"2019","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106054_bib61","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41416-021-01608-2","article-title":"Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients","volume":"126","author":"Gasparetto","year":"2022","journal-title":"Br J Cancer"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.106054_bib62","doi-asserted-by":"crossref","first-page":"12600","DOI":"10.1182\/blood-2022-158060","article-title":"Real-world safety and effectiveness of selinexor-based regimens in patients with relapsed or refractory multiple myeloma and dialysis-dependent renal impairment","volume":"140","author":"Bentur","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106054_bib63","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/ejh.13937","article-title":"A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed\/refractory multiple myeloma","volume":"110","author":"Derman","year":"2023","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106054_bib64","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.clml.2019.12.013","article-title":"Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"20","author":"Salcedo","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.106054_bib65","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/blood-2023-184949","article-title":"Selinexor, ixazomib, pomalidomide and dexamethasone in functionally high-risk multiple myeloma: results from the myeloma development regimens using genomics (MYDRUG) sub-protocol Y3","volume":"142","author":"Richter","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.106054_bib66","first-page":"45","article-title":"Selinexor, lenalidomide and dexamethasone (SRd) for patients with relapsed\/refractory and newly diagnosed multiple myeloma","volume":"136","author":"White","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106054_bib67","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1177\/10781552241235902","article-title":"Selinexor for the treatment of patients with relapsed or refractory multiple myeloma","volume":"30","author":"Babar","year":"2024","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106054_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-79537-2","article-title":"Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease","volume":"14","author":"Yin","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106054_bib69","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jha2.122","article-title":"Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"2","author":"Gasparetto","year":"2020","journal-title":"EJHaem"},{"key":"10.1016\/j.esmoop.2025.106054_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1352281","article-title":"Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"14","author":"White","year":"2024","journal-title":"Front Oncol"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.106054_bib71","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.1182\/blood-2023-185540","article-title":"Selinexor, daratumumab and dexamethasone for patients with multiple myeloma previously treated with lenalidomide at first relapse: a real-world study","volume":"142","author":"Zhai","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.esmoop.2025.106054_bib72","first-page":"2219","article-title":"Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study","volume":"109","author":"Gonz\u00e1lez-Calle","year":"2024","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.106054_bib73","doi-asserted-by":"crossref","first-page":"7051","DOI":"10.1182\/blood-2024-197887","article-title":"Selinexor combined with daratumumab, thalidomide, and dexamethasone in patients with first relapsed multiple myeloma: a single-arm, multicenter, prospective study","volume":"144","author":"Chen","year":"2024","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.esmoop.2025.106054_bib74","article-title":"Interim results of the launch study-a multicenter, open-label study of selinexor, dexamethasone and chemotherapy drugs in relapsed\/ refractory multiple myeloma","volume":"7","author":"Sun","year":"2023","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.106054_bib75","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1182\/blood-2024-206877","article-title":"A novel conditioning regimen combining selinexor with melphalan could improve survival of patients with multiple myeloma","volume":"144","author":"Ma","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.106054_bib76","first-page":"3095","article-title":"Phase I\/II study of liposomal doxorubicin (DOX) in combination with selinexor (SEL) and dexamethasone (DEX) for relapsed and refractory multiple myeloma (RRMM)","volume":"130","author":"Baz","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106054_bib77","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41698-022-00315-2","article-title":"Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)","volume":"6","author":"Nguyen","year":"2022","journal-title":"NPJ Precis Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.esmoop.2025.106054_bib78","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1182\/blood-2021-146925","article-title":"Combination venetoclax and selinexor effective in relapsed\/refractory multiple myeloma with translocation t(11;14)","volume":"138","author":"Nguyen","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.106054_bib79","doi-asserted-by":"crossref","first-page":"6740","DOI":"10.1182\/blood-2023-180939","article-title":"Selinexor, venetoclax, and dexamethasone in t(11;14)-positive relapsed\/refractory multiple myeloma (SELVEDge Study)","volume":"142","author":"Kazandjian","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106054_bib80","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/1535-7163.MCT-16-0496","article-title":"Clinical dosing regimen of selinexor maintains normal immune homeostasis and T-cell effector function in mice: implications for combination with immunotherapy","volume":"16","author":"Tyler","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106054_bib81","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3892\/or.2021.8121","article-title":"Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19-positive malignancies","volume":"46","author":"Wang","year":"2021","journal-title":"Oncol Rep"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.106054_bib82","article-title":"Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment","volume":"41","author":"Baljevic","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.106054_bib83","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1186\/s12967-023-04655-w","article-title":"A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed\/refractory extramedullary multiple myeloma","volume":"21","author":"Wang","year":"2023","journal-title":"J Transl Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925019246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925019246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:04:17Z","timestamp":1776099857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925019246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2059702925019246"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.106054","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.106054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106054"}}